These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 22525394)

  • 21. Effectiveness of omalizumab in a patient with severe asthma, low serum IgE level, and lack of sensitized allergens induced by oral steroid therapy: the usefulness of impulse oscillation for assessment of omalizumab therapy.
    Matsuno O; Komori C; Hang Y; Matsumoto T; Minamoto S
    J Asthma; 2012 Oct; 49(8):839-42. PubMed ID: 22920591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Profile of patients treated with omalizumab in routine clinical practice in Spain.
    Ancochea J; Chivato T; Casan P; Picado C; Herráez L; Casafont J
    Allergol Immunopathol (Madr); 2014; 42(2):102-8. PubMed ID: 23267505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.
    Solèr M; Matz J; Townley R; Buhl R; O'Brien J; Fox H; Thirlwell J; Gupta N; Della Cioppa G
    Eur Respir J; 2001 Aug; 18(2):254-61. PubMed ID: 11529281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.
    Burch J; Griffin S; McKenna C; Walker S; Paton J; Wright K; Woolacott N
    Pharmacoeconomics; 2012 Nov; 30(11):991-1004. PubMed ID: 22950547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
    Dal Negro RW; Tognella S; Pradelli L
    J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
    J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Retrospective analysis of omalizumab in patients with severe allergic asthma].
    Padullés Zamora N; Comas Sugrañes D; Méndez Cabaleiro N; Figueras Suriol A; Jodar Masanes R
    Farm Hosp; 2013; 37(5):399-405. PubMed ID: 24128103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal study of the expression of FcεRI and IgE on basophils and dendritic cells in association with basophil function in two patients with severe allergic asthma treated with Omalizumab.
    Pereira Santos MC; Campos Melo A; Caetano A; Caiado J; Mendes A; Pereira Barbosa M; Branco Ferreira M
    Eur Ann Allergy Clin Immunol; 2015 Mar; 47(2):38-40. PubMed ID: 25781192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control.
    Molimard M; Mala L; Bourdeix I; Le Gros V
    Respir Med; 2014 Apr; 108(4):571-6. PubMed ID: 24565601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients.
    Riccio AM; Dal Negro RW; Micheletto C; De Ferrari L; Folli C; Chiappori A; Canonica GW
    Int J Immunopathol Pharmacol; 2012; 25(2):475-84. PubMed ID: 22697079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical experience with omalizumab in a Portuguese severe asthma unit.
    Alfarroba S; Videira W; Galvão-Lucas C; Carvalho F; Bárbara C
    Rev Port Pneumol; 2014; 20(2):78-83. PubMed ID: 24525397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.
    Holgate S; Bousquet J; Wenzel S; Fox H; Liu J; Castellsague J
    Curr Med Res Opin; 2001; 17(4):233-40. PubMed ID: 11922396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry.
    de Llano LP; Vennera Mdel C; Álvarez FJ; Medina JF; Borderías L; Pellicer C; González H; Gullón JA; Martínez-Moragón E; Sabadell C; Zamarro S; Picado C;
    J Asthma; 2013 Apr; 50(3):296-301. PubMed ID: 23350994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Omalizumab, recombinant humanized monoclonal antibody anti-IgE -- new fields of studies on the therapeutic indications].
    Kupryś-Lipińska I; Kuna P
    Pneumonol Alergol Pol; 2009; 77(1):43-51. PubMed ID: 19308909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Omalizumab is effective in the long-term control of severe allergic asthma.
    Lanier BQ; Corren J; Lumry W; Liu J; Fowler-Taylor A; Gupta N
    Ann Allergy Asthma Immunol; 2003 Aug; 91(2):154-9. PubMed ID: 12952109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis.
    Busse WW; Massanari M; Kianifard F; Geba GP
    Curr Med Res Opin; 2007 Oct; 23(10):2379-86. PubMed ID: 17711616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-IgE for chronic asthma.
    Walker S; Monteil M; Phelan K; Lasserson TJ; Walters EH
    Cochrane Database Syst Rev; 2003; (3):CD003559. PubMed ID: 12917972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Omalizumab in the treatment of asthma.
    Tan R; Corren J
    Expert Rev Respir Med; 2011 Dec; 5(6):747-56. PubMed ID: 22082161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.